Investment Survey Reveals Increased Confidence in Biotechnology Sector
46% of respondents were more optimistic about the biotech sector than 12 months ago, while only 11% were less so. The biotechnology market was considered on average to be fairly valued by the investors and analysts, while 57% of biotechnology company executives considered the market somewhat or very much undervalued. 77% of respondents agreed that the greatest value driver for biotechnology is developing therapeutics for untreatable medical conditions and filling the pharma industry's R&D pipeline.
The greatest threats to the industry were considered to be:
1. insufficient availability of funding to sustain development (45% of biotechnology respondents)
2. the inability of companies to translate innovation into marketable drugs
Interestingly, in the wake of several recent high-profile product withdrawals (Vioxx, Tysabri), safety issues were considered to be of moderate importance but not the overriding concern.
The long-term perspectives for the biotech sector were judged highly or generally favourable by 87% of all respondents, and an equivalent 87% of the investor/analyst group were recommending investments in biotechnology.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.